SOPH Earnings Prediction
The chart below shows how SOPH performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SOPH sees a +6.81% change in stock price 10 days leading up to the earnings, and a +2.18% change 10 days following the report. On the earnings day itself, the stock moves by -1.55%. This data can give you a slight idea of what to expect for the next quarter's release.
SOPH Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
17.73M
4.02%
11.86%
Gross Margin
68.25%
-2.22%
1.56%
Operating Margin
-98.37%
-11.49%
1.51%
Net Margin
-85.48%
-39.44%
-26.51%
EPS
-0.23
-37.84%
-17.86%
No Data Available
SOPH Earnings Analysis
Sophia Genetics SA Corporation (SOPH.O) Earnings Conference Call
Positive
Foundational Year for Growth: 2024 was a foundational year for SOPHiA, laying groundwork for accelerated growth in 2025 and 2026 by signing an impressive cohort of new customers.
Revenue and Margin Performance: In 2024, SOPHiA delivered $65.2 million of revenue, falling within guidance range, and exceeded expectations on cost management with adjusted gross margin reaching 72.8%.
Patient Analysis Milestone: SOPHiA analyzed a record 352,000 patients on SOPHiA DDM in 2024, averaging almost 30,000 patients per month, showcasing the platform's widespread use.
Customer Acquisition Milestone: The company signed a record 92 new core genomic customers in 2024, including 31 in Q4, and implemented a record 35 new customers in Q4 alone.
Clinical Revenue Growth: Clinical revenue grew 23% in the U.S. in 2024, with analysis volume growing 26%, indicating strong market momentum.
Strategic Partnership Expansion: SOPHiA signed Mount Sinai, a leading hospital, for HemOnc and SolidTumors applications, further expanding its U.S. presence.
Liquid Biopsy Adoption Expansion: The launch of MSK-ACCESS has enabled hospitals to conduct Liquid Biopsy testing, with 34 customers across 20 countries adopting the application.
U.S. Business Pipeline Growth: SOPHiA's new business pipeline in the U.S. is up more than 100%, indicating strong future growth potential.
Revenue Forecast for 2025: The company expects to report full year revenue between $72 million and $76 million for 2025, representing 10% to 17% growth on a reported basis.
Negative
BioPharma Budget Constraints: BioPharma budgets tightened across the industry, materially impacting SOPHiA's BioPharma business.
Revenue Performance Analysis: Total revenue for 2024 was $65.2 million, representing only 4% year-over-year growth, which is below long-term expectations.
BioPharma Revenue Decline: The company experienced a decline in BioPharma-related revenue by approximately $4 million in 2024.
Customer Acquisition Impact: Latin America saw a notable decline in performance due to the acquisition of a top customer by another lab, although they have since rewon the business.
Hereditary Cancer Growth Moderation: Hereditary Cancers applications experienced a slight moderation in growth as labs shifted to Exome applications.
Cash Burn Increase: Total cash burn for Q4 2024 was $15.6 million, an increase from $9.5 million in the prior year quarter, largely due to exchange rate impacts.
Customer Revenue Retention Decline: The dollar retention rate decreased to 104% in 2024, indicating a slight decline in customer revenue retention.
Exchange Rate Impact Forecast: The company anticipates a moderate negative impact from exchange rates on reported results in 2025.
SOPH FAQs
How does SOPH typically perform around its earnings report dates?
Is Sophia Genetics SA (SOPH) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SOPH Earning Call Sentiment
SOPHiA GENETICS SA (NASDAQ:SOPH) Q4 2024 Earnings Call Transcript
SOPH.O
3.21%Positive
The earnings call reveals competitive pressures and customer churn, leading to revenue growth below expectations. Exchange rate volatility and economic uncertainties further dampen the outlook. Although there are improvements in adjusted margins and operating losses, cash burn increased, and there's no shareholder return plan. Management's vague responses in the Q&A add to concerns. Overall, the negative factors outweigh the positives, suggesting a likely stock price decline in the short term.
